Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vagus Nerve Stimulation For Heart Failure Fails To Impress, But BioControl Not Bothered

This article was originally published in The Pink Sheet Daily

Executive Summary

Data from two trials of vagus nerve stimulation to treat heart failure, sponsored by Boston Scientific and Cyberonics, respectively, were not particularly positive for the future of this therapy. But another developer of a VNS system for heart failure, BioControl, says the results won’t affect its chances for approval.

You may also be interested in...



Cardio3 BioSciences Ups R&D Efforts After CV Stem Cell Product Clears Safety Review

Belgian regenerative therapies company plans to enlarge its R&D and partnering efforts after a pre-planned interim review by a Data Safety Monitoring Board gave the Phase III study of lead product C-Cure a clean bill of health.

Cardio3 BioSciences Ups R&D Efforts After CV Stem Cell Product Clears Safety Review

Belgian regenerative therapies company plans to enlarge its R&D and partnering efforts after a pre-planned interim review by a Data Safety Monitoring Board gave the Phase III study of lead product C-Cure a clean bill of health.

European Approval For BioControl Medical’s Nerve Stimulation System For Treatment-Resistant Depression

BioControl Medical’s FitNeS vagus nerve stimulation system now has a second approved European indication: treatment-resistant depression. This follows the implantable neuromodulation system’s first CE mark for drug-resistant epilepsy in 2010.

Related Content

Related Companies

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel